Table 1.
Cell type | Identification markers | Normal activity | Prometastatic activity | References |
---|---|---|---|---|
CSC | Nanog Oct-4 SOX-2 Lgr-5 CD133 CD24 CD29 ALDH1 EpCAM CD44 CD166 CD26 |
Not present in healthy tissues | Tumor development, chemoattractant activity (SDF-1/CXCL12) | (6) |
CAFs | CD44 a-SMA PDGFR-b Desmin FAP FSP MFAP5 TN-C PDPN NG2 |
Extracellular matrix synthesis of collagen and elastin. | Secretion of growth factors EGF, IL-6, ILGF, HGF, improve angiogenesis, and remodel of ECM | (7–12) |
MSCs | CD105 CD73 CD44 CD90 |
Components of stroma, immunomodulatory functions | Improve cell proliferation, angiogenesis, and metastasis by the secretion of CXCL12, IL-6, IL-8, and differentiation in CAFs | (11, 13, 14) |
Pericytes | PDGFRβ CD13 NG2 CSPG4 a-SMA Desmin RGS5 CFTR/MRP SUR2 ALP Vimentin CD133 CD146. |
Protection of endothelial cells in capillaries, blood flow regulation, and inflammatory cell trafficking | Secretion of growth factors HGF, FGFs, and CXCL12 that promote the growth, survival of malignant cells, and function as a chemoattractant | (5, 15–17) |
Tregs | CD4 CD25 FoxP3 CD127 |
Maintenance of immune tolerance | Inactivation of CD8+ T-cells' cytotoxic activities, improvement of angiogenesis, and myeloid cell recruitment. Bad prognostic indicator | (11, 18–20) |
Tumor-associated macrophages (TAM) -M1 -M2 |
CD14, CD16, CD64, CD68, CD71 CCR5 |
Proinflammatory cells specialized in pathogen destruction and enhancing activation of cytotoxic lymphocytes Anti-inflammatory cells that stimulate a CD4+ and regulatory T-cell response |
Elimination of malignant cells. High production of NO TNFα, CXCL9, and CXCL10 Activate secretion of IL-6, TGFβ, EGF, bFGF, and IL-10, and VEGF to enhance tumor growth |
(3, 11) |